** CVS Health CVS.N raised its full-year profit forecast on Thursday after beating Wall Street's quarterly earning estimates as tight oversight of higher medical costs improved performance of its Aetna health insurance business
** Rivals including UnitedHealth UNH.N, Elevance ELV.N and Centene CNC.N have warned of higher-than-expected medical costs in the second-quarter.
** 20 out of 29 analysts rate stock as buy or higher, 9 hold; Median PT is $80 - LSEG
CVS HEALTH ON THE RIGHT TRACK
** Evercore ISI ("outperform," PT: $85) says CVS is moving with clearer operational focus and sharper discipline under new management
** Leerink Partners ("outperform," PT: $86) says majority of the moving parts in the health care benefits segment are on the right track
** "We continue to see more tailwinds than headwinds" - brokerage
** Morningstar (fair value: $92) says CVS's profit forecast raise sets it apart from peers like CNC, ELV and UNH that cut 2025 guidance after weak results
** TD Cowen ("buy," PT: $95) says they believe second-half guidance still has room for upside
(Reporting by Twesha Dikshit)
((Twesha.Dikshit@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.